Table 1.
Clinical and disease characteristics
| Pt | Diagnosis | Age | Prior regimens | Stage | BM+ | Flu R | Rit R | Response | KIR-L MM | Time to next therapy (days) | Subsequent therapy | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Marginal zone lymphoma | 48 | 5 | IVB | Yes | Yes | Yes | CR | Yes Bw4 | 116 | MRD HCT | Alive in CR 6 + months |
| 2 | Follicular lymphoma | 49 | 4 | IVB | Yes | Yes | Yes | CR | Yes C2 | 70 | MRD HCT | Alive in CR 5 + months |
| 3 | Transformed lymphoma | 57 | 5 | IVB | Yes | Yes | Yes | PR | No | 62 | DUCB HCT | Alive, relapse at 6 months |
| 4 | DLBCL | 76 | 6 + XRT | IEA | No | N | Yes | PR | Yes C1 | 123 | Chemotherapy | Alive, relapse at 6 months |
| 5 | DLBCL | 48 | 3 | IVB | No | N | Yes | NR | No | 45 | Clinical trial | Dead |
| 6 | Transformed lymphoma | 35 | 3 + XRT | IIEA | No | N | Yes | NR | No | – | Palliative care | Dead |
DLBCL diffuse large B cell lymphoma, N not received, BM bone marrow, flu fludarabine, rit rituximab, XRT radiation therapy, CR complete remission, PR partial remission, NR no response, Flu R fludarabine refractory, Rit R rituximab refractory, MRD matched related donor, DUCB double umbilical cord blood, HCT hematopoietic cell transplantation, KIR-LMM killer immunoglobulin receptor-ligand (class I HLA mismatch) in graft versus host direction